University of Arkansas
Welcome,         Profile    Billing    Logout  
 61 Trials 
121 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Douglas, James G
CATCO, NCT04330690: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Active, not recruiting
3
2900
Canada
Artesunate, Imatinib, Infliximab, Dexamethasone, LSALT Peptide
Sunnybrook Health Sciences Centre, AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc.
COVID-19
03/24
05/24
Lewis, Gary F
PALISADE, NCT05089084 / 2021-003680-10: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting
3
75
Europe, Canada, Japan, US, RoW
Plozasiran, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Familial Chylomicronemia
04/24
04/26
VOICE, NCT04648020 / 2021-000999-11: Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.

Terminated
2b
190
Europe, US
Clonidine HCl Mucoadhesive Buccal Tablet, Validive®, Placebo Mucoadhesive Buccal Tablet
Monopar Therapeutics, Monopar Therapeutics Inc.
Chemoradiotherapy-Induced Severe Oral Mucositis
05/23
05/23
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

Recruiting
N/A
86
Canada, US, RoW
DaRT seeds, DaRT
Alpha Tau Medical LTD.
Recurrent Squamous Cell Carcinoma
12/24
12/25
James, Laura
POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Recruiting
N/A
5000
Canada, US
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab
Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
09/26
09/27
Courtney, Sherry
NCT02261883 / 2023-001028-40: Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Terminated
2
42
US
IV Remodulin, Treprostinil, Placebo
United Therapeutics, United Therapeutics Corp
Persistent Pulmonary Hypertension of the Newborn
09/22
05/23
PIVOTAL, NCT05547165: Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

Recruiting
N/A
240
US
Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac
Nationwide Children's Hospital, National Institutes of Health (NIH), Abbott, University of Pittsburgh, University of Bristol, Dartmouth College, University of Iowa, Emory University, Cedars-Sinai Medical Center, Children's Hospital Los Angeles, National Heart, Lung, and Blood Institute (NHLBI)
Ductus Arteriosus, Patent
02/26
02/26
Contact, Central
NCT03641560: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Completed
4
52
RoW
Enzalutamide, MDV3100, Xtandi, Androgen deprivation therapy (ADT)
Astellas Pharma Inc
Metastatic Castration Resistant Prostate Cancer
02/24
02/24
NCT03684018 / 2018-003430-33: Two Dose Levels of Privigen in Pediatric CIDP

Recruiting
4
30
US
IgPro10, Privigen
CSL Behring
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12/29
12/29
NCT02294461: An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Completed
3
395
RoW
Enzalutamide, Xtandi, MDV3100, Placebo
Astellas Pharma Inc
Progressive Metastatic Prostate Cancer
09/15
07/24
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Recruiting
3
177
Canada, US
IgPro20, HIZENTRA®, Placebo
CSL Behring
Post-COVID Postural Orthostatic Tachycardia Syndrome
09/27
09/27
NCT06617897: Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Recruiting
3
90
Europe
CSL511 Fibrinogen concentrate (human), Cryoprecipitate
CSL Behring
Acquired Fibrinogen Deficiency
09/26
10/26
TAP, NCT05568888: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( Study )

Terminated
3
1370
Europe, US, RoW
BE1116, 4-Factor Prothrombin Complex, Kcentra®, Beriplex®, Placebo
CSL Behring
Traumatic Injury
10/24
10/24
NCT02430220: The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors

Active, not recruiting
2
152
RoW
Regorafenib (CT), BAY 73-4506, Regorafenib (STIVARGA)
Cancer Centre of Monoclonal Therapy, LLC, Clinical Cancer Hospital, Bayer
Solid Tumors, Colorectal Cancer
04/18
09/18
HERALD, NCT06342947: ALG-055009 in Non-cirrhotic Adults With MASH

Active, not recruiting
2
100
US
ALG-055009, Placebo
Aligos Therapeutics
NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
11/24
12/24
NCT06545916: Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder

Recruiting
2
200
US
Sunobinop, V117957, Placebo to match sunobinop
Imbrium Therapeutics, Purdue Pharma LP
Alcohol Use Disorder
07/25
07/25
NCT06285214: Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

Completed
1
47
US
V117957, Placebo
Imbrium Therapeutics, Purdue Pharma LP
Interstitial Cystitis/Bladder Pain Syndrome
01/25
01/25
NCT04285827: Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

Completed
1
28
Europe, US
CSL889
CSL Behring
Sickle Cell Disease
07/23
07/23
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
08/25
05/29
NCT06364696: A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

Recruiting
1
175
US
ASP4396
Astellas Pharma Inc
Solid Tumor
04/27
04/27
NCT06171178: A Study of ASP1012 in Adults With Solid Tumors

Recruiting
1
229
US
ASP1012, Pembrolizumab
Astellas Pharma Global Development, Inc.
Solid Tumor
06/29
06/29
NCT06248086: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

Terminated
1
1
RoW
ASP2802, MACT, MA-20, ASP101G, MicAbody
Astellas Pharma Global Development, Inc.
B-cell Lymphoma
12/24
12/24
NCT06024642: Study of V117957 in Overactive Bladder Syndrome

Completed
1
51
US
V117957, Placebo
Imbrium Therapeutics, Purdue Pharma LP
Overactive Bladder Syndrome
05/24
05/24
NCT03292887: Hunter Outcome Survey (HOS)

Completed
N/A
1443
US
Shire
Hunter Syndrome
02/23
02/23
NCT03291223: Gaucher Disease Outcome Survey (GOS)

Recruiting
N/A
1257
US
Shire
Gaucher Disease
09/25
09/25
NCT06734585: Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant

Recruiting
N/A
200
RoW
Gilteritinib, ASP2215, XOSPATA®
Astellas Pharma Singapore Pte. Ltd.
Acute Myeloid Leukemia
06/25
06/25
OPTION-VMS, NCT06049797: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

Recruiting
N/A
1000
US
Fezolinetant, ESN364, VEOZAH, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
Astellas Pharma Global Development, Inc.
Hot Flashes
02/26
11/26
NCT03971253: Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

Recruiting
N/A
3000
Japan
Peficitinib, ASP015K, Smyraf
Astellas Pharma Inc
Rheumatoid Arthritis (RA)
12/25
12/25
NCT05886348: The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens

Active, not recruiting
N/A
249
RoW
Model-A Novel spectacle lens, Model-B Novel spectacle lens, Single vision spectacle lens
HOYA Lens Thailand LTD.
Myopia
05/26
05/27
NCT06011954: A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

Recruiting
N/A
202
RoW
Enfortumab Vedotin, PADCEV, ASG-22CE
Astellas Pharma Korea, Inc., Seagen Inc.
Urothelial Cancer
07/27
07/27
Willmott, Lyndsay
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
ZN-c3-004, NCT04814108: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Recruiting
2
76
Canada, US, RoW
ZN-c3, azenosertib, KP-2638
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Uterine Serous Carcinoma
11/24
05/25
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
PRESERVE-004, NCT05446298: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Active, not recruiting
2
58
US
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, MK3475, Keytruda
OncoC4, Inc., Merck Sharp & Dohme LLC, GOG Foundation
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
06/25
06/26
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
Rizk, Dana
EAGLE, NCT03749447 / 2018-003253-24: An Extended Access Program for Bardoxolone Methyl in Patients With CKD

Terminated
3
270
Europe, Japan, US, RoW
Bardoxolone methyl, RTA 402
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc.
Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
08/23
08/23
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -

Terminated
3
667
Europe, Japan, US, RoW
Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC
Autosomal Dominant Polycystic Kidney, ADPKD
08/23
08/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
REBOOT, NCT03949855: Belimumab With Rituximab for Primary Membranous Nephropathy

Recruiting
2
58
Canada, US
Belimumab, Benlysta®, Placebo for Belimumab, Belimumab placebo, Rituximab, Rituxan®
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), GlaxoSmithKline, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Membranous Nephropathy, Nephrotic Syndrome
03/29
03/30
ASSIST, NCT05834738: Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

Recruiting
2
52
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
10/25
08/26
TBD, TBD
INFRONT-3, NCT04374136 / 2019-004066-18: A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia

Active, not recruiting
3
110
Europe, Canada, US, RoW
AL001, Placebo, Open label - AL001
Alector Inc.
Frontotemporal Dementia
09/25
10/27
NCT04105452: Study to Evaluate PL8177 in Subjects With Non Infectious Uveitis (NIU)

Not yet recruiting
2
40
NA
PL8177
Palatin Technologies
Non-infectious Uveitis
05/20
09/20
NEO-SURG, NCT06449313: Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

Not yet recruiting
2
21
US
Cemiplimab-Rwlc, Libtayo
Georgetown University, Regeneron Pharmaceuticals
Non-small Cell Lung Cancer Stage III
12/27
09/32
INVOKE-2, NCT04592874 / 2019-001476-11: A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

Completed
2
381
Europe, Canada, US, RoW
AL002, Placebo
Alector Inc., AbbVie
Alzheimer Disease
08/24
09/24
NCT05744401 / 2022-002987-57: A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

Active, not recruiting
2
188
Europe, Canada, US, RoW
AL002
Alector Inc., AbbVie
Alzheimer's Disease
09/25
12/25
CAR, NCT06215105: Complex Aneurysm Registry - Real-World Evidence Data Collection Intracranial Aneurysm Treatment Devices

Enrolling by invitation
N/A
750
US
Intracranial Aneurysm Devices
Microvention-Terumo, Inc.
Aneurysm Cerebral
01/29
01/29
NCT05876078: DORAYA-HF OUS Assessment of the Doraya Catheter for the Treatment of ADHF Patients With Insufficient Response to Diuretics

Recruiting
N/A
35
Europe, RoW
Doraya catheter
Revamp Medical Ltd.
Acute Decompensated Heart Failure
12/25
04/26
NCT03173664: Post-Approval Study With the KAMRA Inlay

Not yet recruiting
N/A
529
NA
KAMRA Inlay
AcuFocus, Inc.
Presbyopia
01/26
01/26
GPS Registry, NCT05027685: The "Global Paradise System" Registry

Recruiting
N/A
3000
Europe, RoW
The Paradise Ultrasound Renal Denervation System
ReCor Medical, Inc.
Hypertension
12/30
12/31
C19REG, NCT04331860: COVID-19 Public Image Registry

Recruiting
N/A
500000
US
No intervention
RAD-AID International, BioClinica, Inc., Google Inc.
COVID-19
03/25
03/25
Coordinator, Research
CAMPLIFE, NCT06562296: Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers

Recruiting
4
292
US
Amnion-Intermediate-Chorion, AIC, Amnion-Chorion-Amnion, ACA, Standard of Care, SOC
Cellution Biologics, SerenaGroup, Inc., LifeCell
Diabetic Foot Ulcer, Venous Leg Ulcer
12/26
07/27
NCT05078827: Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

Completed
3
458
US
Test Product (A): Fluorouracil Cream, 5% topical cream, Experimental, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Active Comparator, Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India, Placebo Comparator
Encube Ethicals Pvt. Ltd., CBCC Global Research
Actinic Keratoses
11/22
12/22
ReMMi-D, NCT05853900: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

Completed
3
558
US
ReMMi-D Digital Therapeutic
Click Therapeutics, Inc.
Migraine, Episodic Migraine, Headache, Headache, Migraine
05/24
05/24
OPERA-T, NCT05238116 / 2021-004554-32: Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis ( Study)

Recruiting
3
123
Europe, Canada, US, RoW
PC945, Placebo
Pulmocide Ltd
Refractory IPA
03/26
04/26
NCT06004388: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

Completed
3
110
US
Click Digital Therapeutic
Click Therapeutics, Inc.
Migraine, Episodic Migraine, Headache, Headache, Migraine
05/24
06/24
CONVOKE, NCT05838625: Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

Recruiting
3
432
US
Digital Therapeutic
Click Therapeutics, Inc., Boehringer Ingelheim
Schizophrenia
06/25
07/25
NCT06067984: An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

Active, not recruiting
3
75
US
Study App
Click Therapeutics, Inc., Boehringer Ingelheim
Schizophrenia, Negative Symptoms in Schizophrenia
04/25
05/25
NCT06365437: A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Completed
2
33
Europe
TCD601, Siplizumab, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG
ITB-Med LLC
Kidney Transplantation
12/24
12/24
PHYOX8, NCT05001269 / 2021-001083-16: Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

Recruiting
2
25
Europe, Canada, Japan, US, RoW
nedosiran, DCR-PHXC
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3
12/24
12/24
CHASE, NCT05727878: Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED

Recruiting
2
90
US, RoW
KPI-012, KPI-012 Vehicle
Combangio, Inc, Kala Pharmaceuticals, Inc.
Persistent Corneal Epithelial Defect
03/25
10/25
NCT05733546: A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Recruiting
2
102
US
Psilocybin, COMP360
COMPASS Pathways
Major Depressive Disorder
10/24
11/24
NCT04270175: Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Recruiting
2
21
US
Daratumumab SC, Faspro, Pomalidomide, Dexamethasone
Weill Medical College of Cornell University, Janssen Scientific Affairs, LLC
Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
12/25
12/29
NCT04803058: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)

Recruiting
2
18
US, RoW
TCD601
ITB-Med LLC
Kidney Transplantation
03/27
03/30
STRIDE, NCT06025110: A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

Active, not recruiting
2
96
Europe
TCD601, Placebo
ITB-Med LLC
Diabetes Mellitus, Type 1
01/25
01/25
ASCEND, NCT05669001: A Study of TCD601 in de Novo Renal Transplant Recipients

Recruiting
2
90
US
TCD601, siplizumab, belatacept, ATG, antithymocyte globulin, TAC, tacrolimus, MPA, mycophenolic acid, Corticosteroids
ITB-Med LLC
Renal Transplantation
07/25
10/26
NCT04311632: A Dose Escalation Study in de Novo Renal Transplantation

Completed
2
13
US
TCD601, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG
ITB-Med LLC
Kidney Transplantation
10/23
10/23
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26
NCT04803006: A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

Recruiting
2
18
US
TCD601
ITB-Med LLC
Kidney Transplantation
07/27
07/30
AURORA, NCT06453668: A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

Active, not recruiting
1
48
Europe
TCD601, siplizumab
ITB-Med LLC
ALS
11/26
11/26
PBL-0405-01, NCT06273852: A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Recruiting
1
15
US
PBA-0405, PB004.22.0405.aF
Pure Biologics S.A., Presage Biosciences
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
03/25
03/25
MST01-AZN-05, NCT06366451: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC

Recruiting
1
15
US
Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475
Presage Biosciences, AstraZeneca
Head and Neck Squamous Cell Carcinoma
12/24
03/25
OP-1250-003, NCT05508906: Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus

Recruiting
1
155
US, RoW
OP-1250, Ribociclib, KISQALI®, Alpelisib, PIQRAY®, Everolimus
Olema Pharmaceuticals, Inc., Novartis
Metastatic Breast Cancer, Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer
05/26
06/26
NCT06798454: Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)

Recruiting
1
30
RoW
PVT201, Navacim, Placebo, normal saline, 0.9% NaCl
Parvus Therapeutics, Inc., Avance Clinical Pty Ltd.
Primary Biliary Cholangitis (PBC)
02/25
02/25
NCT04541108: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting
1
15
US
Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475
Presage Biosciences, Merck Sharp & Dohme LLC
Solid Tumor
12/31
12/31
NCT06802328: Treatment Protocol: Intermediate-Size Patient Population Expanded Access

Available
N/A
US
Foralumab TZLS-401 50 µg
Tiziana Life Sciences LTD
Non-Active Secondary Progressive Multiple Sclerosis
 
 
NCT06136936: A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

Completed
N/A
53
US
CT-156-C-001
Click Therapeutics, Inc., Boehringer Ingelheim
Schizophrenia
01/24
02/24
NCT05222581: Engineering Evaluation of a Breast Pump Device

Recruiting
N/A
20
US
Prototypes of breast shield and Freedom Double Electric Breast Pump
Momtech Inc.
Healthy, Breast Pumping
09/24
11/24
NCT06136923: An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer

Completed
N/A
194
US
CT-100-D-004-A, CT-100-D-004-B
Click Therapeutics, Inc.
Multiple Sclerosis, Lung Cancer, Breast Cancer
04/24
05/24
LOCAL, NCT04968847: FemaSeed Artificial Insemination Trial

Completed
N/A
314
US
FemaSeed Localized Directional Insemination
Femasys Inc.
Infertility, Male Factor
12/23
04/24
CT-100-D-003, NCT06275659: An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

Active, not recruiting
N/A
120
US
CT-100-004-A, CT-100-004-B
Click Therapeutics, Inc.
Psoriasis, Atopic Dermatitis
02/24
03/24
NCT05119842: APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study

Recruiting
N/A
30
Europe, US
APrevent® VOIS-Implant
APrevent Biotech GmbH
Paralysis, Unilateral, Vocal Cord
09/25
09/26
Lublin, NCT06217081: 3M™ Topical Tissue Adhesive Versus Commercially Available Tissue Adhesive for the Closure of Lacerations and Incisions

Recruiting
N/A
452
US
3M Topical Tissue Adhesive, Histoacryl® Blue Topical Skin Adhesive
Solventum US LLC, United States Department of Defense, The University of Texas Health Science Center at San Antonio, 3M
Trauma-related Wound, Surgical Incision, Surgical Wound, Laceration
11/25
12/25
CoMind EFS, NCT06368648: CoMind Early Feasibility Study

Recruiting
N/A
581
US
CoMind Technologies Limited, Lindus Health
Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage, Encephalitis, Encephalopathy, Hydrocephalus, Stroke, Autoregulation
10/25
10/25
NCT05006404: Autus Valve Pivotal Study

Recruiting
N/A
50
US
Pulmonary Valve Replacement Surgery
Autus Valve Technologies, Inc.
Congenital Heart Disease
08/26
02/36
MASTR, NCT05243966: Myriad™ Augmented Soft Tissue Reconstruction Registry

Recruiting
N/A
800
US
Myriad Matrix™ and Myriad Morcells™
Aroa Biosurgery Limited
Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, Lower Extremity Wound, Pilonidal Sinus, Anal Fistula, Hidradenitis Suppurativa, Pressure Injury
01/28
01/29
NCT06770998: A Study of a Novel EEG Neurofeedback System for PTSD Treatment

Not yet recruiting
N/A
250
US
EEG-neurofeedback training, Prism training, amyg-EFP training, active Prism training, Sham training, sham Prism training
Foundation for Atlanta Veterans Education and Research, Inc., GrayMatters Health Ltd., Rochester Institute of Technology, New York University Grossman School of Medicine, Atlanta VA Medical Center, Birmingham VA Health Care System, Ralph H. Johnson VA Medical Center, VA Boston Healthcare System, CTP Inc, BioStats Statistical Consulting Ltd, ShareCRF, United States Department of Defense
Stress Disorders, Post-Traumatic
06/27
08/27
PHONES, NCT04662320: Promoting Healing of Nerves Through Electrical Stimulation

Active, not recruiting
N/A
100
US
Checkpoint BEST System, Brief Electrical Stimulation (BES) Therapy
Checkpoint Surgical Inc., Congressionally Directed Medical Research Programs
Cubital Tunnel Syndrome, Nerve Compression, Nerve Injury, Ulnar Neuropathies
12/25
12/25
FINALE, NCT05977751: Prospective Multi-Center Trial for FemBloc Permanent Birth Control

Recruiting
N/A
573
US
FemBloc
Femasys Inc.
Contraception
12/29
06/31
PHINEST, NCT05884125: Promoting Healing of Injured Nerves With Electrical Stimulation Therapy

Recruiting
N/A
60
US
Checkpoint BEST System, Brief Electrical Stimulation (BES) Therapy
Checkpoint Surgical Inc., Congressionally Directed Medical Research Programs
Nerve Injury, Peripheral Nerve Injuries, Peripheral Nerve Injury Upper Limb, Nerve Palsy
06/27
06/27
NCT05678530: Observational, Non-Interventional Study Supporting Validation of VO2Max Estimation Methods Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)

Recruiting
N/A
400
Canada, US
Prolaio
Cardiopulmonary
06/25
06/25
Padilla, Michelle
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Terminated
3
130
US
AB-205, E-CEL cells, Placebo
Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
Hodgkin Lymphoma, Non Hodgkin Lymphoma
12/23
01/25
ARTEMIS, NCT04511130: Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

Completed
2
47
US
MT-401, zedenoleucel
Marker Therapeutics, Inc.
Acute Myeloid Leukemia, Stem Cell Transplantation
03/24
03/24
VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
24
US
VCAR33
Vor Biopharma
Leukemia, Myeloid, Acute
10/25
11/26
ANTLER, NCT04637763: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

Recruiting
1
72
US, RoW
CB-010, Cyclophosphamide, Fludarabine
Caribou Biosciences, Inc.
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
08/25
09/25
NCT05309733: A Long-term Follow-up Study of Patients Who Received VOR33

Recruiting
N/A
36
Canada, US
VOR33
Vor Biopharma
Leukemia, Myeloid, Acute
01/40
01/40
Tharian, Benjamin
TARGET-HCC, NCT02954094: A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Recruiting
N/A
10000
Europe, US
Target PharmaSolutions, Inc.
Hepatocellular Cancer
10/25
10/25
Garcia, Mauricio K
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
 

Download Options